Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options

Por Jiang, Hanfang, Rugo, Hope S.
Publicado no Ther Adv Med Oncol (2015)

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer

Por Chien, A. Jo, Rugo, Hope S.
Publicado em 2012

Amelioration of sexual adverse effects in the early breast cancer patient

Por Melisko, Michelle E., Goldman, Mindy, Rugo, Hope S.
Publicado em 2010

The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting

Por Palli, Swetha Rao, Grabner, Michael, Quimbo, Ralph A, Rugo, Hope S
Publicado no Cancer Manag Res (2015)

Immune microenvironments in solid tumors: new targets for therapy

Por Shiao, Stephen L., Ganesan, A. Preethi, Rugo, Hope S., Coussens, Lisa M.
Publicado em 2011

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting

Por Hesketh, Paul J., Aapro, Matti, Jordan, Karin, Schwartzberg, Lee, Bosnjak, Snezana, Rugo, Hope
Publicado no Biomed Res Int (2015)

Leukocyte composition of human breast cancer

Por Ruffell, Brian, Au, Alfred, Rugo, Hope S., Esserman, Laura J., Hwang, E. Shelley, Coussens, Lisa M.
Publicado em 2012

Clinical and biomarker predictors of side effects from tamoxifen

Por Lorizio, Wendy, Wu, Alan H.B, Beattie, Mary S., Rugo, Hope, Tchu, Simone, Kerlikowske, Karla, Ziv, Elad
Publicado em 2011

Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis

Por Belkora, Jeffrey K, Rugo, Hope S, Moore, Dan H, Hutton, David W, Chen, Daniel F, Esserman, Laura J
Publicado em 2009

First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER

Por Tripathy, Debu, Kaufman, Peter A., Brufsky, Adam M., Mayer, Musa, Yood, Marianne Ulcickas, Yoo, Bongin, Quah, Cheng, Yardley, Denise, Rugo, Hope S.
Publicado em 2013

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer

Por Yardley, Denise A., Kaufman, Peter A., Brufsky, Adam, Yood, Marianne Ulcickas, Rugo, Hope, Mayer, Musa, Quah, Cheng, Yoo, Bongin, Tripathy, Debu
Publicado em 2014

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment

Por Lorizio, Wendy, Rugo, Hope, Beattie, Mary S, Tchu, Simone, Melese, Teri, Melisko, Michelle, Wu, Alan HB, Lawrence, H Jeffrey, Nikoloff, Michele, Ziv, Elad
Publicado em 2011

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer

Por Rugo, Hope S., Brufsky, Adam M., Yood, Marianne Ulcickas, Tripathy, Debu, Kaufman, Peter A., Mayer, Musa, Yoo, Bongin, Abidoye, Oyewale O., Yardley, Denise A.
Publicado em 2013

Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients

Por Magbanua, Mark Jesus M., Sosa, Eduardo V., Roy, Ritu, Eisenbud, Lauren E., Scott, Janet H., Olshen, Adam, Pinkel, Dan, Rugo, Hope, Park, John W.
Publicado em 2012

Macrophage IL-10 blocks CD8(+) T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells

Por Ruffell, Brian, Chang-Strachan, Debbie, Chan, Vivien, Rosenbusch, Alexander, Ho, Christine M.T., Pryer, Nancy, Daniel, Dylan, Hwang, E. Shelley, Rugo, Hope S., Coussens, Lisa M.
Publicado no Cancer Cell (2014)

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study

Por Kaufman, Peter A., Brufsky, Adam M., Mayer, Musa, Rugo, Hope S., Tripathy, Debu, Yood, Marianne Ulcickas, Feng, Shibao, Wang, Lisa I., Quah, Cheng S., Yardley, Denise A.
Publicado em 2012

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer...

Por Tripathy, Debu, Rugo, Hope S, Kaufman, Peter A, Swain, Sandra, O’Shaughnessy, Joyce, Jahanzeb, Mohammad, Mason, Ginny, Beattie, Mary, Yoo, Bongin, Lai, Catherine, Masaquel, Anthony, Hurvitz, Sara
Publicado em 2014

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of...

Por Aapro, Matti, Karthaus, Meinolf, Schwartzberg, Lee, Bondarenko, Igor, Sarosiek, Tomasz, Oprean, Cristina, Cardona-Huerta, Servando, Hansen, Vincent, Rossi, Giorgia, Rizzi, Giada, Borroni, Maria Elisa, Rugo, Hope
Publicado no Support Care Cancer (2016)

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer

Por Rugo, Hope S., Campone, Mario, Amadori, Dino, Aldrighetti, Daniela, Conte, PierFranco, Wardley, Andrew, Villanueva, Cristian, Melisko, Michelle, McHenry, M. Brent, Liu, David, Lee, Francis, Pivot, Xavier
Publicado em 2013

Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer

Por Chien, A. Jo, Munster, Pamela N., Melisko, Michelle E., Rugo, Hope S., Park, John W., Goga, Andrei, Auerback, Glenna, Khanafshar, Elham, Ordovas, Karen, Koch, Kevin M., Moasser, Mark M.
Publicado em 2014